Article Text

Download PDFPDF

2022-RA-1696-ESGO Impact of ERAS implementation for vulvar cancer surgery
  1. Thomas Warkus1,
  2. Audrey Feng-Emond2,
  3. Annick Orvoine Serra Pina1,
  4. Elise de Castro Hillmann3 and
  5. Vanessa Samouëlian1
  1. 1Gynecology Oncology, CHUM, Montreal, QC, Canada
  2. 2Faculty of Medecine, University of Montreal, Montreal, QC, Canada
  3. 3Gynecology oncology, CHUM Research Center, Montreal, QC, Canada


Introduction/Background Surgical literature and information on vulvar cancer is restricted. Centre hospitalier de l’Université de Montréal(CHUM) has a high volume of vulvar cancer patients. Gynaecological Enhanced Recovery after Surgery(ERAS) guidelines was implemented in 2017. This study compares CHUM’s practices to available ERAS guidelines, evaluates ERAS compliance and the impact of its implementation on vulvar cancer outcome.

Methodology A retrospective cohort study was conducted at CHUM and included vulvar cancer patients operated in 2015 (pre-ERAS implementation) and 2019–2020 (post-ERAS implementation). Same day discharge and non-elective patients were excluded. Vulvar surgery and gynaecologic oncology ERAS guidelines were compared to CHUM’s practices by comparing protocol items. ERAS impact was measured by comparing pre-post implementation cohorts: length of stay (LOS), rates of complications, readmissions, and survival outcomes. Statistical significance was 0.05.

Abstract 2022-RA-1696-ESGO Table 1

. Comparison between ERAS vulvar surgery and gyneocologic surgery guidelines and CHUM’s practices

Results 78.9% of CHUM’s practices correspond with ERAS vulvar surgery guidelines (table 1). 113 patients were analysed: 51(45.1%) pre-ERAS and 62(54.9%) post-ERAS. Histological types were 69,9% squamous-cell carcinoma, 5.3% adenocarcinoma, 4.4% melanoma, 5.3% squamous-cell carcinoma with other components, 9.7% persistent VIN-III, and 5.3% Paget’s disease. 73.5% of patients had primary treatment and 23% had an adjuvant treatment. Compliance increased from 50.84% pre-ERAS to 56.89% post-ERAS (p=0.523). Post-operative LOS significantly decreased from 7 to 3 nights (p=0.004). No serious complication occurred during hospitalisation, only one serious complication in post-ERAS cohort occurred after hospitalisation. Readmissions decreased from 11.8% to 4.8% (p=0.173). Survival analysis was conducted on stages I-II squamous-cell carcinoma; no significant difference was found between pre-post implementation on overall survival (p=0.277) and disease-free survival (p=0.671).

Conclusion Although CHUM’s practices correspond to 78.9% of the ERAS vulvar surgery guidelines, our compliance remains below 60% and did not significantly increase after ERAS implementation. This might be due to a lack of documentation in patients’ record. The main impact of ERAS implementation was the LOS significant decrease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.